FdaApplication
BLA 020725
Identifiers
- fda_app_no: BLA020725
Properties
| Property | Value |
|---|---|
| applicant_name | AbbVie Inc. |
| application_type | BLA |
| approval_date | 2009-04-30 |
Revenue by product
CREON
| Period | Revenue |
|---|---|
| Q2 2026 | $345.0M |
| Q1 2026 | $361.0M |
| Q4 2025 | $385.0M |
| Q3 2025 | $368.0M |
| Q2 2025 | $404.0M |
| Q1 2025 | $355.0M |
| Q4 2024 | $388.0M |
| Q3 2024 | $338.0M |
| Q2 2024 | $372.0M |
| Q1 2024 | $285.0M |
| Q4 2023 | $376.0M |
| Q3 2023 | $305.0M |
| Q2 2023 | $282.0M |
| Q1 2023 | $305.0M |
| Q4 2022 | $337.0M |
| Q3 2022 | $336.0M |
| Q2 2022 | $318.0M |
| Q1 2022 | $287.0M |
| Q4 2021 | $327.0M |
| Q3 2021 | $310.0M |
| Q2 2021 | $280.0M |
| Q1 2021 | $274.0M |
| Q4 2020 | $304.0M |
| Q3 2020 | $282.0M |
| Q2 2020 | $252.0M |
| Q1 2020 | $276.0M |
| Q4 2019 | $292.0M |
| Q3 2019 | $265.0M |
| Q2 2019 | $257.0M |
| Q1 2019 | $227.0M |
| Q4 2018 | $261.0M |
| Q3 2018 | $239.0M |
| Q2 2018 | $219.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (5)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| CREON | PANCRELIPASE (AMYLASE; LIPASE; PROTEASE) | 24,000USP UNITS; 76,000USP UNITS; 120,000USP UNITS | Capsule, Delayed Release |
| CREON | PANCRELIPASE (AMYLASE; LIPASE; PROTEASE) | 36,000USP UNITS; 114,000USP UNITS; 180,000USP UNITS | Capsule, Delayed Release |
| CREON | PANCRELIPASE (AMYLASE; LIPASE; PROTEASE) | 6,000USP UNITS; 19,000USP UNITS; 30,000USP UNITS | Capsule, Delayed Release |
| CREON | PANCRELIPASE (AMYLASE; LIPASE; PROTEASE) | 12,000USP UNITS; 38,000USP UNITS; 60,000USP UNITS | Capsule, Delayed Release |
| CREON | PANCRELIPASE (AMYLASE; LIPASE; PROTEASE) | 3,000USP UNITS; 9,500USP UNITS; 15,000USP UNITS | Capsule, Delayed Release |
5 products